gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Polo-like kinase 2

SNK, Plk2, Polo-like kinase 2, serum-inducible kinase
The protein encoded by this gene is a member of the polo family of serine/threonine protein kinases that have a role in normal cell division. This gene is most abundantly expressed in testis, spleen and fetal tissues, and its expression is inducible by serum, suggesting that it may also play an important role in cells undergoing rapid cell division. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2011] (from NCBI)
Top mentioned proteins: CAN, Plk1, Anova, Plk3, HAD
Papers on SNK
PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells.
New
Lu et al., Guangzhou, China. In Cancer Med, Jan 2016
Polo-like kinase 2 (PLK2) plays an important role in bone development.
Effects of Serine 129 phosphorylation on α-synuclein aggregation, membrane association, and internalization.
New
Tandon et al., Toronto, Canada. In J Biol Chem, Jan 2016
Here, co-expression of α-syn and polo-like kinase 2 (PLK2), a kinase that targets S129, was used to generate phosphorylated α-syn for biophysical and biological characterization.
Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
New
Kim et al., Seoul, South Korea. In Ann Oncol, Jan 2016
We suspected that these events were associated with Epstein-Barr virus (EBV) reactivation because of the rapidly elevated EBV DNA titers in blood from these patients.An in vitro study with the ENKTL cell line SNK-6 cells also showed that histone deacetylase inhibitors including romidepsin increased the copy number of EBV DNA in a dose-dependent manner.
MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer.
New
Molloy et al., Australia. In Int J Radiat Oncol Biol Phys, Jan 2016
The expression of putative microRNA target biomarkers-TOP2A, POLQ, RAD54L, SKP2, PLK2, and RAG1-were correlated with standard clinicopathologic variables using 2-sided nonparametric tests, and to local/distant relapse and survival using Kaplan-Meier and Cox regression analysis.
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
New
Reddy et al., New York City, United States. In Bioorg Med Chem, Jan 2016
PLK2 (SNK), which is highly homologous to PLK1, has been shown to play a critical role in centriole duplication and is also believed to play a regulatory role in the survival pathway by physically stabilizing the TSC1/2 complex in tumor cells under hypoxic conditions.
[Study of exogenous carbon monoxide-releasing molecules 2 on endotoxin/lipopolysaccharide-induced abnormal activation of platelets of healthy human donors].
New
Sun et al., Zhenjiang, China. In Zhonghua Shao Shang Za Zhi, Oct 2015
Data were processed with one-way analysis of variance and SNK test.
[Effects of blocking two sites of transforming growth factor-β/Smads signaling on the formation of scar-related proteins in human skin fibroblasts].
New
Xu et al., Hangzhou, China. In Zhonghua Shao Shang Za Zhi, Oct 2015
Data were processed with one-way analysis of variance and SNK-(q test).
[Effects of adipose-derived mesenchymal stem cells over-expressing glial cell line-derived neurotrophic factor on electrically injured sciatic nerve of rats].
New
Chaowu et al., In Zhonghua Shao Shang Za Zhi, Jun 2015
Data were processed with one-way analysis of variance, analysis of variance of repeated measurement, and SNK test.
Polo-like kinase 2 acting as a promoter in human tumor cells with an abundance of TAp73.
Lu et al., Guangzhou, China. In Onco Targets Ther, 2014
Polo-like kinase 2 (PLK2) displayed a close relationship with the p53 family in affecting the fate of cells.
Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development.
Review
Fiedler et al., Hamburg, Germany. In Future Oncol, 2014
Volasertib is a potent inhibitor of Polo-like kinase (PLK) 1 and to lesser extent also PLK2 and PLK3.
Superiority of PLK-2 as α-synuclein phosphorylating agent relies on unique specificity determinants.
GeneRIF
Pinna et al., Padova, Italy. In Biochem Biophys Res Commun, 2012
PLK2 and to a lesser extent PLK3 are superior over CK2, as catalysts of Ser-129 phosphorylation both in full length alpha-synuclein and in a peptide reproducing the C-terminal segment of the protein.
Upregulation of Polo-like kinase 2 gene expression by GATA-1 acetylation in human osteosarcoma MG-63 cells.
GeneRIF
Fu et al., Shenyang, China. In Int J Biochem Cell Biol, 2012
Acetylation of GATA-1 responsive elements in Polo-like kinase 2 plays a crucial role in Plk2 transcription and protein expression in MG-63 cells.
Identification and functional characterization of polo-like kinase 2 autoregulatory sites.
GeneRIF
Pak et al., Washington, D.C., United States. In Neuroscience, 2012
phosphorylation sites could play an important role in the rapid activation, expansion, and prolongation of Plk2 signaling
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.
Review
GeneRIF
Syed et al., Guildford, United Kingdom. In Oncotarget, 2012
The methylation status of the PLK2 CpG island predicts outcomes in patients treated with carboplatin and paclitaxel chemotherapy.
Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.
GeneRIF
Di Agostino et al., Roma, Italy. In Cell Cycle, 2012
Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.
Kinases as targets for Parkinson's disease: from genetics to therapy.
Review
Taymans et al., Leuven, Belgium. In Cns Neurol Disord Drug Targets, 2011
Two of these kinases stand out as potential drug targets for novel PD therapy, namely leucine rich repeat kinase 2 (LRRK2) and the alpha-synuclein (α-syn) phosphorylating polo-like kinase 2 (PLK2).
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
Review
Impact
Strebhardt, Frankfurt am Main, Germany. In Nat Rev Drug Discov, 2010
The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1-cyclin B1 and Aurora kinases to orchestrate a wide range of critical cell cycle events.
p53 and its downstream proteins as molecular targets of cancer.
Review
Sun, Ann Arbor, United States. In Mol Carcinog, 2006
A follow-up study characterized a p53-repressed gene, SAK, a polo-like kinase (PLK) family member, as an appealing cancer drug target.
Targeted protein degradation and synapse remodeling by an inducible protein kinase.
Impact
GeneRIF
Sheng et al., Cambridge, United States. In Science, 2003
induction in hippocampal neurons eliminated SPAR protein, depleted PSD-95 and Bassoon clusters & caused loss of mature dendritic spines; results implicate SNK as a mediator of activity-dependent change in the molecular composition & morphology of synapses
share on facebooktweetadd +1mail to friends